newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Announces the Sale of Select Development Programs and the Wind-Down of its Operations

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. today announced the sale of its zilovertamab and ONCT-808 programs to Ho'ola Therapeutics, Inc. Zilovertamab is an investigational monoclonal